Clinical Significance and Correlation Decomposition of Cord Blood NO, Activin A Levels, and MCA/UA with Fetal Distress.

The clinical significance and correlation of cord blood NO, activin A levels, and middle cerebral artery (MCA)/umbilical artery (UA) with fetal distress are explored. 120 puerperae who delivered in the obstetrics department of our hospital from January 2021 to January 2022 are selected as the examination subjects. According to the diagnostic criteria of fetal distress, they are divided into 70 cases of fetal distress and 50 cases of normal delivery. The parameters of umbilical cord blood NO, activin A, UA, and MCA are contrast between the two sets, then the diagnostic value of umbilical cord blood NO and activin A combined with UA and MCA in fetal distress is analyzed. The experimental results show cord blood NO and activin A combined with UA and MCA have a high diagnostic value for fetal distress, and there is an extensive correlation with the occurrence of fetal distress, which provides a reliable clinical diagnosis of fetal distress in a timely manner.

Elevated Circulating Levels of Glycoprotein Non-Metastatic Melanoma Protein B as a Predictor of Gestational Diabetes Mellitus.

BACKGROUND: The current study aims to investigate the differences of glycoprotein non-metastatic melanoma protein B (GPNMB) levels between gestational diabetes mellitus (GDM) women and normal blood glucose women during pregnancy to provide the basis for early intervention and treatment of GDM. METHODS: The level of GPNMB was detected using an enzyme-linked immunosorbent assay (ELISA). Pearson's correlation assay was performed to analyze the correlation between serum GPNMB and fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). The receiver operating characteristic (ROC) curve was carried out to analyze the diagnostic value of serum GPNMB. RESULTS: Our data showed that the serum GPNMB level in GDM group was higher than that in normal blood glucose group at 5 - 12 weeks, 13 - 23 weeks, and 24 - 28 weeks of gestation, but there was no significant difference at 29 - 37 weeks of gestation. Meanwhile, the total level of serum GPNMB in GDM group was significantly higher than that in normal blood glucose group. Further study indicated that serum GPNMB positively correlated with FPG (r = 0.562, p < 0.0001) or HbA1c (r = 0.652, p < 0.0001). ROC analysis showed that serum GPNMB level at 13 - 23 weeks of gestation had a good predictive effect on predicting GDM at 24 weeks of gestation and beyond. When the cutoff value of serum GPNMB level was 2.46 µg/L, the sensitivity and specificity were 80% and 72%, respectively. CONCLUSIONS: The serum GPNMB level at 13 - 23 weeks of gestation is an independent risk factor for GDM in 24 weeks and beyond, and early inhibition with GPNMB may provide a preventive measure in GDM women.

Elevated Serum and Urine MiR-429 Contributes to the Progression of Gestational Diabetes Mellitus.

BACKGROUND: The current study aims to explore a noninvasive molecular marker that can evaluate the therapeutic effect and prognosis of gestational diabetes mellitus (GDM). METHODS: Differentially expressed miRs were identified using microarray assay and the findings were verified using RT-PCR. Receiver operating characteristic (ROC) was performed to explore the diagnostic value of serum and urine miR-429 in GDM women. The relationship between miR-429 and homeostatic model assessment-insulin resistance (HOMA-IR) was analyzed using Pearson's correlation assay. Dual luciferase assay and western blot were carried out to explore the possible target gene of miR-429. RESULTS: Microarray assay and RT-PCR showed that miR-429 was found to be significantly increased in both serum and urine samples of GDM women compared with those of normal blood glucose pregnancy group (NGT). Also, the expression of miR-429 in serum and urine was positively correlated with HOMA-IR. ROC analysis showed that both serum and urine miR-429 could screen GDM from NGT. Furthermore, dual luciferase reporter and western blot assay indicated that insulin receptor substrate- (IRS-) 1 was a target gene of miR-429. CONCLUSIONS: In summary, the increase of serum and urine miR-429 level is a risk factor of insulin resistance in pregnant women with GDM.